Seeking Alpha

Celgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma...

Celgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma study with Abraxane for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal. Results from the study show that the drug demonstrates significant improvement in progression-free survival when compared to standard chemotherapy in advanced melanoma patients. (abstract)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs